An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Harrow (Nasdaq: HROW) to participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023. CEO and CFO to hold fireside chat and one-on-one investor meetings.
Positive
Harrow to participate in B. Riley Securities 23rd Annual Institutional Investor Conference
CEO and CFO to hold fireside chat and one-on-one investor meetings
Negative
None.
NASHVILLE, Tenn.--(BUSINESS WIRE)--
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will participate in the upcoming B. Riley Securities 23rd Annual Institutional Investor Conference on Wednesday, May 24, 2023, at the Beverly Hilton Hotel in Beverly Hills, California.
Harrow’s Chief Executive Officer, Mark L. Baum, and Chief Financial Officer, Andrew Boll, will participate in a fireside chat on Wednesday, May 24th at 9:00 a.m. Pacific time, with one-on-one investor meetings held throughout the day.
To receive additional information, request an invitation, or schedule a one-on-one meeting with Harrow management, please contact your B. Riley Securities representative.
About Harrow
Harrow (Nasdaq: HROW) is a leading U.S. eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic prescription therapies that are accessible and affordable. Harrow owns U.S. commercial rights to ten FDA-approved ophthalmic pharmaceutical products. Harrow also owns and operates ImprimisRx, the leading U.S. ophthalmic-focused pharmaceutical compounding business, which also serves as a mail‑order pharmacy licensed to ship prescription medications in all 50 states. Harrow has non‑controlling equity positions in Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc., companies that began as subsidiaries of Harrow. Harrow also owns royalty rights in four late-stage drug candidates being developed by Surface and Melt.
